MedTech commercial teams can now reuse and build on AI-generated intelligence across recurring workflows, reducing repetitive work for AcuityAI users

AcuityMD, the AI platform for MedTech, today announced AcuityAI Artifacts, a new capability that transforms AI-generated insights into structured, reusable content for commercial teams. With Artifacts, users can turn AcuityAI conversations into call plans, market analyses, account comparisons, targeting lists, and reports that can be easily saved, refined, and exported. Artifacts ensure valuable insights extend beyond a single conversation, enabling teams to continuously build on and benefit from that intelligence.

Artifacts can be generated from any information available in AcuityAI. The agent automatically selects the most appropriate output format based on the user’s request such as a chart, ranked list, or comparison table. Users can take these documents based on AcuityAI responses and refine them over time as well as export them as polished AcuityMD-branded content.

"AcuityAI already gives commercial teams the answers they need, and now Artifacts makes those answers something the whole team can use," said Brian Collins, Chief Product Officer at AcuityMD. "A rep can build a targeting list once and share it with their manager; a commercial leader can carry the same account view from one QBR to the next instead of rebuilding it every time. This is how AI evolves from just answering individual questions to becoming an integral part of how a commercial team collaborates and makes decisions.”

AcuityAI Artifacts is available now to all AcuityMD customers.

About AcuityMD
AcuityMD is the AI platform for MedTech trusted by over 500 MedTech companies – including 16 of the top 20. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261028218483/en/

AcuityAI already gives MedTech commercial teams the answers they need, and now Artifacts makes those answers something the whole team can use, reducing repetitive work and time.